Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.62 |
| ▸ | PI4KA | P42356 | 2/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.62 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440175 | 1.00 | ADORA2A (0.77) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| Phosphoric Acid SCHEMBL20305062 | 0.94 | ADORA2A (0.70) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL26130576 | 0.89 | ADORA2A (0.79) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL30367149 | 0.89 | ADORA2A (0.79) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL16081003 | 0.88 | ADORA2A (0.81) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL1865640 | 0.87 | ADORA2A (0.61) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL24837583 | 0.87 | ADORA2A (1.00) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL12300485 | 0.87 | ADORA2A (1.00) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5559348 | 0.87 | ADORA2A (0.79) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL21081913 | 0.87 | ADORA2A (1.00) | ADORA2AADORA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240191231-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2024-06-13 | — | — | US | claimed |
| CN-117925755-A | Synthesis method of nucleoside intermediate 2' -O-methyl guanosine | 康羽生命科学技术(苏州)有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2023154964-A1 | METHODS AND COMPOSITIONS FOR TARGETING EFEMP1 | ALLOY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2022-04-14 | — | — | US | claimed |
| US-20220090071-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2022-03-24 | — | — | US | claimed |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2021-10-05 | — | — | US | claimed |
| US-11053503-B2 | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | KCL THERAPEUTICS, INC | 2021-07-06 | — | — | US | claimed |
| WO-2021117122-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR LYSOSOMAL ACID LIPASE DEFICIENCY SYNDROME | 株式会社リボルナバイオサイエンス | 2021-06-17 | — | — | WO | claimed |
| US-20190292540-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2019-09-26 | — | — | US | claimed |
| US-7838657-B2 | compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (intronic splicing silencer), located in the SMN2 gene | UNIVERSITY OF MASSACHUSETTS (US) | 2010-11-23 | — | — | US | claimed |
| US-20100087511-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIVERSITY OF MASSACHUSETTS (US) | 2010-04-08 | — | — | US | claimed |
| US-20070292408-A1 | Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2007-12-20 | — | — | US | claimed |
| EP-1556402-A4 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIV MASSACHUSETTS (US) | 2007-10-10 | — | — | EP | claimed |
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1556402-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | University of Massachusetts (US) | 2005-07-27 | — | — | EP | claimed |
| US-20050020521-A1 | Rna interference strands and antibody strands | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | US | claimed |
| WO-2004029212-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-08 | — | — | WO | claimed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | claimed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | SNRPE, AGO2, NSUN2 | ADORA2A 2178/4885ADORA3 2303/4885PI4KA 3628/4885 |
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | PNP, MTAP, GALE | ADORA2A 486/4885ADORA3 503/4885PI4KA 537/4885 |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | PNP, GALE, MTAP | ADORA2A 464/4885ADORA3 544/4885PI4KA 508/4885 |
| US-20050020521-A1 | Rna interference strands and antibody strands | AGO2, NSUN3, NSUN2 | ADORA2A 1935/4885ADORA3 1516/4885PI4KA 2060/4885 |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | ADORA2A 2178/4885ADORA3 2303/4885PI4KA 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.